Arexis Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $10.1M

Arexis General Information

Description

Operator of a pharmaceutical company intended to develop metabolic and inflammatory disease therapeutics. The company's research is biology-driven with proprietary technology and a focus on the development of pharmaceuticals for the treatment of lipid malabsorption, diabetes, atopic dermatitis (inflammatory skin disease) and rheumatoid arthritis, enabling doctors with novel therapies to easily treat patients.

Contact Information

Website
www.arexis.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Arvid Wallgrens Backe
  • 413 46 Gothenburg
  • Sweden
+46 031-749
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Biovitrum
Vertical(s)
Life Sciences
Corporate Office
  • Arvid Wallgrens Backe
  • 413 46 Gothenburg
  • Sweden
+46 031-749

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arexis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 22-Aug-2005 $10.1M Completed Clinical Trials - General
3. Early Stage VC 01-Jul-2003 Completed Startup
2. Early Stage VC 30-May-2001 $4.64M $4.64M Completed Startup
1. Early Stage VC Completed Startup
To view Arexis’s complete valuation and funding history, request access »

Arexis Patents

  • 170

    Total Documents Applications and Grants

  • Total Patents Families

  • 56

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Arexis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170333812-A1 An improved manufacturing method Active 31-Oct-2014
US-10625180-B2 Manufacturing method Active 31-Oct-2014
US-20120156235-A1 Antibodies against and methods for producing vaccines for respiratory syncytial virus Active 02-Feb-2009
US-20150125479-A1 Antibodies against and methods for producing vaccines for respiratory syncytial virus Active 02-Feb-2009
US-8852608-B2 Antibodies against and methods for producing vaccines for respiratory syncytial virus Inactive 02-Feb-2009 C07K14/005
To view Arexis’s complete patent history, request access »

Arexis Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
3i Group PE/Buyout Minority
Industrifonden Venture Capital Minority
InnovationsKapital Venture Capital Minority
Kreos Capital Lender/Debt Provider Minority
Skandinaviska Enskilda Banken Investment Bank Minority
To view Arexis’s complete investors history, request access »

Ready to get started?

Request a free trial

Arexis FAQs

  • When was Arexis founded?

    Arexis was founded in 1999.

  • Where is Arexis headquartered?

    Arexis is headquartered in Gothenburg, Sweden.

  • What industry is Arexis in?

    Arexis’s primary industry is Drug Discovery.

  • Is Arexis a private or public company?

    Arexis is a Private company.

  • What is the current valuation of Arexis?

    The current valuation of Arexis is .

  • What is Arexis’s current revenue?

    The current revenue for Arexis is .

  • How much funding has Arexis raised over time?

    Arexis has raised $12.7M.

  • Who are Arexis’s investors?

    3i Group, Industrifonden, InnovationsKapital, Kreos Capital, and Skandinaviska Enskilda Banken have invested in Arexis.

  • When was Arexis acquired?

    Arexis was acquired on 22-Aug-2005.

  • Who acquired Arexis?

    Arexis was acquired by Biovitrum.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process